Nocira
Tempe, ArizonaFounded 2017
- Neuromodulation
- Series B
- Migraine
Nocira is a medical technology company developing an investigational, non-invasive device system for acute migraine treatment. Its approach uses controlled air-pressure changes in the ear to stimulate sensory nerves and influence pain-processing centers in the brain.
- RaisedTotal raised
- $9.5M
- Jun 2017Latest priced round, Jun 2017
- Series B
- Investor
- 1
- Founded
- 2017
- Employees
- 1–10
reccy insights
Nocira’s identifiable milestones center on its migraine-treatment technology rather than a steady stream of corporate announcements. The company raised a $9.5 million Series B on Jun 12, 2017, with AZ Crown Investments as lead investor. Subsequent patent activity points to continued work on its ear-based pressure approach: an external ear canal pressure regulation device was documented in 2021, an ear-pump patent in 2022, and filings concerning a magnetically driven pressure generator and pressure adjustment devices appeared in 2023 and 2024. These developments align with Nocira’s described investigational system, which delivers controlled air-pressure pulses into the ear and is paired with a mobile application. A Aug 25, 2026 headline about Avulux migraine lenses is not a Nocira milestone and is excluded.
Written by reccy's AI from company sites, press and funding records · updated Oct 2026
What makes Nocira distinct
- 01Developing a non-invasive alternative to medication and injections for acute migraine treatment.
- 02Uses controlled air-pressure changes in the ear to stimulate sensory nerve pathways.
- 03Pairs the investigational treatment device with a mobile platform for device control and therapy tracking.
- 04Designed to offer a treatment experience that may avoid medication-related side effects; clinical benefits are not established here.
Technology & products3
- Investigational Migraine Treatment Device
A non-invasive medical device designed to treat migraines by delivering modulated air-pressure pulses into the ear to stimulate pressure-activated sensory neurons.
- Mobile App for Device Control
A mobile application that controls the migraine treatment device, allowing users to enter migraine information and monitor therapy progress.
- Clinical Trial
A double-blinded, randomized, placebo-controlled, multi-center clinical trial intended to evaluate the device’s clinical effectiveness and safety.
Funding
- Series BJun 2017$9.5MLed by AZ Crown Investments
Similar companies
About Nocira
- Products
- Investigational Migraine Treatment Device, Mobile App for Device Control, Clinical Trial
- Leadership
- Jim Peacock, CEODavid George, Co-Founder, Chief Scientific Officer, and VP of Product DevelopmentTim Crown, Chairman of the Board and Co-FounderHarshal Deshpande, Chief Commercial Officer
- Focus areas
- NeuroTechnology, medical devices, digital health, clinical research, therapeutics, migraine, neuromodulation, neurology
- Headquarters
- Tempe, Arizona
- Founded
- 2017
- Employees
- 1–10
- Patents granted
- 20
- Trademarks
- 1